Technetium-99m Market Report Scope & Overview:

The Technetium-99m Market was valued at USD 6.80 Billion in 2025 and is expected to reach USD 10.77 Billion by 2035, growing at a CAGR of 4.70% from 2026-2035.

The Technetium-99m Market covers generators, radiopharmaceutical kits, ready-to-use radiotracers and emerging cyclotron-produced supply that hospitals and imaging centers use for SPECT-based diagnostic scans. Regulatory clearance pathways govern nearly every step of the value chain, since generators, kits and radiotracers each require separate marketing authorization before a facility can administer them to patients. Tc-99m decays from molybdenum-99, produced at a small number of aging research reactors, which makes reactor-outage risk and approval of alternative production routes central concerns for buyers and regulators alike. North America holds the largest regional share, while national health authorities elsewhere approve new supply routes to reduce reliance on a handful of reactors.

⮞The World Health Organization reported in October 2026 that non-communicable diseases accounted for 74% of the roughly 61 million deaths recorded globally in 2023, up from 58% in 2000, with ischaemic heart disease alone causing 9.5 million deaths. Disease burden of that scale sustains steady demand for the SPECT-based diagnostic scans that depend on regulatory-cleared Tc-99m supply.

U.S. Technetium-99m Market Outlook

The U.S. Technetium-99m Market was valued at USD 2.24 Billion in 2025 and is expected to reach USD 3.60 Billion by 2035, growing at a CAGR of 4.85% from 2026-2035.

U.S. supply runs through a dense nationwide network of nuclear pharmacies that compound and dispense Tc-99m generators and kits under FDA-regulated conditions within hours of delivery. Hospitals and outpatient imaging centers depend on same-day or next-day generator delivery given the isotope's six-hour half-life, which leaves little buffer when a delay occurs. FDA labeling supplements and safety notifications for existing kits are a routine part of compliance, requiring continuous regulatory engagement from manufacturers. Federal support for U.S.-based molybdenum-99 production, including conditional financing for new non-reactor facilities, aims to reduce reliance on imported isotope supply. Consolidation among radiopharmaceutical distributors is concentrating purchasing power while narrowing the number of independent nuclear pharmacy operators.

⮞In October 2026, SHINE SPECT USA listed TechneLite technetium Tc-99m generators in the FDA’s National Drug Code directory, reflecting developments in the U.S. radiopharmaceutical supply landscape and supporting nuclear medicine imaging availability.

By Product Type, Generators Dominate the Technetium-99m Market and Cyclotron-Produced Tc-99m Grows Fastest

Generators hold the leading position because they are the regulatory-approved standard that hospital nuclear pharmacies have relied on for decades, with established marketing authorizations across every major market. A generator ships once and yields repeated daily elutions over roughly one to two weeks, giving facilities a predictable supply rhythm that ready-to-use radiotracers cannot match on cost or logistics grounds. Regulatory filings for new generator suppliers remain demanding, which has kept the approved-supplier base small and reinforced incumbents' position within existing hospital contracts. That combination of regulatory incumbency and operational reliability keeps generators the backbone of Tc-99m procurement across most health systems.

Cyclotron-produced Tc-99m is scaling fastest after Health Canada approved ARTMS Inc.'s cyclotron-based production method in December 2020, the first production route to earn approval outside the traditional reactor-based supply chain. Health authorities view cyclotron production favorably because it can be sited regionally on existing medical cyclotrons, reducing transport time for an isotope with only a six-hour half-life. Licensees are now working to bring the technology to additional cyclotron sites, which regulators treat as incremental approvals rather than a single centralized review. As more sites complete that licensing path, cyclotron-produced supply is expected to keep growing faster than generator-based production from a still-small base, narrowing the gap over the coming decade.

By Modality, Gamma Camera Dominates the Technetium-99m Market and SPECT Grows Fastest

Standalone gamma cameras dominate because they represent the largest installed base worldwide, particularly in facilities that perform routine planar and single-detector studies without needing combined anatomical imaging. Lower acquisition and maintenance costs keep gamma cameras the practical choice for smaller hospitals and clinics operating under tighter capital budgets than large academic medical centers. Regulatory clearance pathways for standalone gamma cameras are well established, with incremental software and detector updates typically following a faster review track than entirely new system submissions. That combination of lower cost and simpler regulatory upgrades keeps standalone gamma cameras the most widely deployed modality for Tc-99m-based studies.

SPECT, particularly combined SPECT/CT, is growing fastest as health systems replace aging single-modality cameras with systems that pair functional imaging with anatomical localization in one study. Newer SPECT/CT systems built around cadmium zinc telluride detectors are winning regulatory clearance on the strength of higher sensitivity, letting facilities maintain image quality without raising patient dose. Reimbursement frameworks in several markets increasingly favor combined SPECT/CT studies over planar-only scans when the clinical pathway calls for precise anatomical correlation. As more replacement cycles favor combined systems, SPECT is expected to keep narrowing the installed-base gap with standalone gamma cameras through 2035 across most major hospital markets.

⮞In September 2026, GE HealthCare said its StarGuide GX digital SPECT/CT system was 510(k) pending with the U.S. FDA and already CE marked, citing up to 2.67 times the system volume sensitivity of its prior NM/CT 870 DR platform. A sensitivity gain of that magnitude in a system still awaiting full U.S. clearance illustrates how active the regulatory pipeline remains for next-generation SPECT hardware.

By Clinical Service, Cardiac Scans Dominate the Technetium-99m Market and Neurology Scans Grow Fastest

Cardiac scans lead clinical demand because myocardial perfusion imaging remains a guideline-supported, reimbursed pathway for evaluating suspected coronary artery disease across a large and aging patient population. Clinical protocols for Tc-99m-based perfusion agents are well codified across cardiology societies, giving referring physicians a standardized, insurance-recognized study to order with predictable turnaround. Hospitals have invested accordingly in dedicated cardiac SPECT capacity and trained technologist staffing, reinforcing cardiac studies as the largest single clinical draw on Tc-99m generator output. That combination of guideline support, reimbursement clarity and dedicated capacity keeps cardiac imaging the dominant clinical service within the category across most developed health systems.

Neurology scans are growing fastest as clinical interest in functional brain imaging expands alongside a rising caseload of neurodegenerative and cerebrovascular disease referrals. Regulatory agencies have cleared several newer Tc-99m-based neurology tracers and imaging protocols in recent years, giving neurologists more standardized options than were available a decade ago. Reimbursement coverage for neurology-focused nuclear imaging remains less uniform than for cardiac studies, but clinical-pathway documentation is gradually closing that gap in several health systems. As that evidence base and coverage continue to expand, neurology scans are expected to keep growing faster than the broader clinical-service category through the remainder of the forecast period to 2035.

⮞The American Heart Association reported in a January 2026 Circulation publication that about 49% of U.S. adults aged 20 and older had some form of cardiovascular disease based on 2021-2023 survey data, with coronary heart disease affecting 5.2%. Disease prevalence of that scale in the reference clinical population underpins continued guideline support for cardiac perfusion imaging referrals.

By End User, Hospitals Dominate the Technetium-99m Market and Diagnostic Imaging Centers Grow Fastest

Hospitals account for the largest share because they hold the regulatory licensing, radiation-safety infrastructure and on-site nuclear pharmacy relationships needed to receive, handle and administer Tc-99m on the tight timeline its six-hour half-life demands. Inpatient and emergency referral pathways for cardiac and other urgent nuclear medicine studies are concentrated in hospital settings, reinforcing their position as the primary site of care. Large hospital systems also negotiate generator supply contracts directly, giving them pricing and allocation priority that smaller independent sites typically cannot match. That combination of regulatory infrastructure and contract leverage keeps hospitals the dominant end-user category for Tc-99m procurement.

Diagnostic imaging centers are growing fastest as outpatient referral volume shifts away from hospital-based scheduling toward freestanding sites offering shorter appointment lead times and lower out-of-pocket patient costs overall. Regulatory requirements for radioactive-material licensing at freestanding centers have become more standardized in several jurisdictions, lowering the compliance barrier for operators opening new sites. Health system affiliations with outpatient imaging networks are also extending hospital-negotiated generator contracts to freestanding locations, improving their supply reliability and pricing terms. As licensing pathways continue to standardize across more jurisdictions, diagnostic imaging centers are expected to keep gaining share of total Tc-99m-based procedure volume through 2035.

⮞In May 2025, the FDA approved a supplemental application from Jubilant DraxImage for Draximage MDP-25, a Tc-99m medronate bone-scan kit, revising its label with new safety information on altered biodistribution. Continued supplemental approvals of that kind for established kits show regulators remain actively engaged with products administered across both hospital and outpatient imaging settings.

Regional Analysis

North America Technetium-99m Market Insights

Holding a 37.70% share in 2025, North America leads the market on the strength of an established nuclear pharmacy network and a regulatory framework that has approved Tc-99m generators, kits and SPECT systems for decades of routine clinical use. The United States supplies 87.40% of regional output, built around FDA-cleared products distributed through a dense network of hospital and nuclear-pharmacy accounts. Federal programs supporting U.S.-based molybdenum-99 production aim to reduce the region's historical reliance on imported isotope supply from reactors overseas. That combination of regulatory maturity and distribution density keeps North America the largest region despite growing competition from faster-expanding markets elsewhere.

Non-uranium production methods are advancing through the U.S. regulatory pipeline as an alternative to imported, highly enriched uranium-based molybdenum-99, reducing proliferation and waste concerns tied to legacy supply routes. Canada continues to play a significant regional role, with power-reactor-based production projects under regulatory review as a complement to traditional research-reactor supply. Hospital consolidation across the region continues to concentrate Tc-99m purchasing among larger health systems with the scale to negotiate multi-year generator contracts. Even with new local production routes advancing, established clinical infrastructure and distribution scale are expected to keep North America the leading region through 2035 despite faster growth elsewhere.

Europe Technetium-99m Market Insights

Europe's market rests on a small number of aging research reactors that have supplied the region's molybdenum-99 for decades, a concentration that national health authorities and the European Commission are now moving to address through a major reactor replacement program. Germany anchors regional clinical demand with a large hospital and nuclear-medicine infrastructure built around established Tc-99m generator and kit suppliers. Scheduled and unscheduled reactor outages in recent years have periodically tightened regional Tc-99m availability, pushing health systems toward tighter coordination with pharmacy networks during maintenance windows. That reliance on a concentrated reactor base, now being addressed through new capacity, defines the region's near-term supply outlook.

A new research reactor under construction in the Netherlands is intended to replace an existing aging facility and secure the region's molybdenum-99 supply once operational in the early 2030s. Regulatory and funding approval for the project came from both the Dutch government and European Union state-aid authorities, reflecting the strategic priority placed on medical isotope security. European nuclear medicine societies continue to support reimbursement pathways for SPECT studies, sustaining steady clinical demand even as production infrastructure is rebuilt. As the new reactor advances toward completion, Europe's supply security is expected to improve gradually through the back half of the forecast period.

⮞The European Commission approved the Dutch government's roughly 2 billion euro public support measure for the PALLAS medical-isotope reactor project in 2024, clearing a major funding hurdle for the facility that broke ground in Petten in September 2025. State-aid approval of that scale for a single reactor project underscores how seriously European regulators treat medical isotope supply security.

Asia Pacific Technetium-99m Market Insights

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of approximately 7.40% from 2026 to 2035, as health systems across China, Japan and India expand capacity from a smaller base. Regulatory agencies across the region have been approving new SPECT and SPECT/CT systems and expanding hospital licensing for radioactive-material handling, lowering barriers for new nuclear medicine departments. Government-backed research reactors in Australia and other regional producers are also expanding their share of global molybdenum-99 supply, reducing the region's historical dependence on imports from Europe and North America. That combination of expanding clinical capacity and growing regional production gives Asia Pacific the fastest growth trajectory among all regions.

Regional producers are refining reactor target designs to extract more molybdenum-99 per irradiation while generating less enriched-uranium waste, directly addressing both cost and non-proliferation concerns that regulators weigh in licensing decisions. China and India are both investing in expanded hospital nuclear medicine infrastructure to serve large, still-underserved patient populations relative to installed SPECT capacity in mature markets. Supply agreements between regional producers and markets outside Asia Pacific are also emerging, extending the region's role beyond serving only local demand. As regional production and clinical capacity continue to scale together, Asia Pacific's share of global Tc-99m supply and consumption is expected to keep rising through 2035.

⮞In February 2026, Australia's national science agency reported progress on a new reusable target design for its OPAL research reactor, which already supplies roughly 8% of global molybdenum-99 production capacity. Incremental yield and waste improvements of that kind at an already-significant regional supplier illustrate how Asia Pacific's production base continues to mature alongside its clinical demand growth.

MEA & Latin America Technetium-99m Market Insights

The Middle East and Africa region depends heavily on South Africa's long-running Safari-1 research reactor, which has supplied molybdenum-99 to hospitals across the region and exported to the United States, Japan and parts of Europe for decades. That reactor is now ageing, prompting a tender process to identify a successor capable of continuing production once the current facility reaches the end of its service life. Elsewhere in the region, most markets rely on imported generators and kits rather than local capacity, leaving them exposed to the same global supply concentration that affects buyers everywhere. Regulatory frameworks for radioactive-material import vary widely, adding complexity for suppliers serving several markets at once.

Latin America is pursuing new international supply partnerships to diversify beyond traditional Northern Hemisphere reactor sources, illustrated by an October 2025 memorandum of understanding between Brazil's National Nuclear Energy Commission (CNEN) and China Isotope & Radiation Corporation covering several isotopes including molybdenum-99. Brazil remains the region's largest nuclear medicine market, drawing on both local research-reactor output and imports to supply its hospital and imaging-center network. Regulatory harmonization efforts across Latin American markets remain uneven, and currency volatility in several countries continues to complicate long-term isotope procurement contracts. Even so, new supply partnerships entering the region point to a gradually diversifying and more resilient Tc-99m supply base through 2035.

⮞NTP Radioisotopes, a subsidiary of South Africa's Necsa, has operated the 20-megawatt Safari-1 research reactor at Pelindaba since 1965 and ranks among the world's top four suppliers of medical radioisotopes, serving the United States, Japan and parts of Europe and the Middle East. A supply role of that scale and longevity from a single ageing reactor underscores both the region's importance to global Tc-99m supply and its exposure to eventual reactor replacement risk.

Market Dynamics

Growth Drivers: Rising chronic disease burden and expanding regulatory clearance of SPECT hardware are lifting procedure volumes

Nuclear medicine procedure volumes keep rising as health systems manage a growing burden of cardiovascular, oncologic and neurodegenerative disease that relies on guideline-supported functional imaging for diagnosis and monitoring. Regulatory clearance of newer SPECT and SPECT/CT systems with improved detector technology is giving hospitals a clinical and economic case to replace aging single-modality cameras sooner than a pure depreciation schedule would otherwise dictate. Reimbursement frameworks in several mature markets increasingly favor well-documented, guideline-backed SPECT pathways over less standardized alternatives, reinforcing procedure volume growth. Together these forces are expanding the installed base of Tc-99m-compatible imaging hardware even as overall healthcare budgets face other competing pressures.

A second driver is the aging of the global population, which expands the pool of patients likely to need cardiac, oncologic or neurological nuclear imaging studies over the coming decade. Health authorities in several countries are responding by fast-tracking regulatory review of local molybdenum-99 production routes, recognizing that rising clinical demand cannot be met safely without a more resilient supply base. Nuclear medicine societies continue to publish updated clinical-pathway guidance that embeds Tc-99m-based studies more firmly into standard diagnostic workups for several common conditions. As the patient population most likely to need these studies continues to grow, procedure-driven demand is expected to outpace headline population growth through 2035.

⮞The United Nations projected in a July 2024 revision of its World Population Prospects that the number of people aged 65 or older will keep rising over the next three decades even in countries with younger, faster-growing populations, eventually outnumbering children under 18 by the late 2070s. A demographic shift of that scale directly expands the patient population most likely to require the cardiac and oncologic SPECT studies that depend on regulatory-cleared Tc-99m supply.

Restraints: Concentrated reactor dependence and ageing supply infrastructure create persistent shortage risk

The market's biggest structural restraint is its dependence on a small number of ageing research reactors for molybdenum-99, several never originally designed for isotope production and now facing difficult spare-parts sourcing. Because Tc-99m's six-hour half-life makes stockpiling impractical, any unplanned reactor outage flows almost immediately into generator shortages at hospitals, creating a just-in-time supply chain with very little buffer. Regulatory approval timelines for qualifying new, non-reactor production routes remain lengthy relative to how quickly an outage can disrupt clinical scheduling, leaving a persistent gap. These pressures are most acute in regions still served by a single ageing reactor rather than a diversified production base.

High production costs and sustained price pressure have historically deterred new entrants from committing capital to molybdenum-99 production, narrowing the supplier base precisely when diversification is most needed. The 2008-2009 global shortage, triggered by an unplanned Canadian reactor shutdown, remains the clearest illustration of how quickly a single-source disruption can cascade into cancelled hospital procedures worldwide. More recent disruptions, including a 2024 structural-repair shutdown at a major European reactor and competition from subsidized foreign producers that pushed one North American producer to halt production in 2023, show the risk has not gone away. Combined, reactor concentration and thin economic margins for new entrants represent the category's most persistent supply-side restraint.

Opportunities: Diversified production routes and power-reactor partnerships open new regulatory pathways

Health authorities reviewing non-reactor and power-reactor-based production routes are creating openings for newer entrants that can demonstrate reliable, regulatory-compliant alternatives to legacy research-reactor supply. Licensing a production method for use at commercial power reactors or distributed medical cyclotrons, rather than building a single centralized facility, allows capacity to scale incrementally as each additional site clears its own regulatory review. Suppliers that secure early approval for these alternative routes stand to capture long-term hospital contracts from health systems eager to reduce their exposure to concentrated reactor-based supply risk. That combination of regulatory openness and incremental scaling gives newer production approaches a credible path to meaningful market share over the next decade.

International supply partnerships between established producers and growing regional markets are opening new revenue channels beyond traditional local customer bases, particularly for suppliers willing to navigate multiple regulatory regimes at once. Government financing support for new local production facilities, including conditional loan commitments, is lowering the capital barrier that has historically deterred new entrants from this capital-intensive, tightly regulated category. Hospitals and imaging centers that qualify for newer SPECT/CT systems with improved sensitivity are also creating replacement-cycle demand that rewards suppliers pairing equipment with reliable supply. Producers and equipment makers that move early into these diversified routes are positioned to capture growth that legacy single-reactor suppliers cannot match.

Technetium-99m Market Key Players

• Curium Pharma

• GE HealthCare Technologies Inc.

• Jubilant Pharmova Limited

• NTP Radioisotopes SOC Ltd.

• Bracco Imaging S.p.A.

• Institute of Isotopes Co., Ltd.

• ANSTO

• NCBJ POLATOM

• ARTMS Inc.

• China Isotope & Radiation Corporation

• Eczacıbaşı-Monrol Nuclear Products

• Eckert & Ziegler SE

• Isotopia Molecular Imaging Ltd.

• Medi-Radiopharma Ltd.

• Rotop Pharmaka GmbH

• NRG PALLAS

• Institute for Radioelements (IRE)

Technetium-99m Market Report Scope: